AllDocs -> cancers

Intravesical EOquin (E09) in theTreatment of Superficial Bladder Cancer JAWitjes,AG van der Heijden Dept Urology,UMCN St Radboud,Nijmegen,the Netherlands Gino Lenaz M.D.,Shanta Chawla M.D. Spectrum Pharmaceuticals,Inc.Irvine,CA 92618 Key words:superficial bladder cancer ;intravesical;Eoquin™ EO9 Abstract EOquin and mitomycin-C (frequently used as intravesical agent in superficial bladder cancer ) are structurally similar but the mechanism of action differs with regard to the ability of oxygen to reverse the activation process and elevated levels of reductases in tumor tissue. Why intravesical application of EOquin?: The bladder is a hypoxic region ;there is a presence of DT-diaphorase enzyme in the bladder ;there is no systemic uptake . In an in vitro experiment we used 4 bladder cancer cell lines that were treated for 60 min.with 0-200 µg/mL MMC or EOquin at 37°C or 43°C.Cell ...

Post AUA 2005 Bladder and Advanced Prostate Cancer Fred Saad CHUM Page 2 SUO • HRPC Tax and combinations • Anti-angiogenisis EGFR • Training Page 3 Bladder Cancer Page 4 A SURVEILLANCE SCHEDULE IN G1TA BLADDER CANCER ALLOWING EFFICIENT USE OF CHECK CYSTOSCOPY AND SAFE DISCHARGE AT 5 YEARS: BASED ON A 25-YEAR PROSPECTIVE DATABASE Paramananthan Mariappan, Edinburgh, United Kingdom 115 patients with G1Ta followed for 19.4 years (range = 19 to 27 years). Tumour status at 3 months strongest prognostic factor for recurrence. If no recurrence to 5 years, 98.3% remained tumour free up to 20 years. Only one patient had a first recurrence after the 5 th year (0.87%). Overall 12% patients experienced progression, mostly ...

· Journal List · Search · Utilities PubMed Central Abstract Full Text Figures/Tables PDF Contents Archive PubMed Articles by: Willis, C. Church, S. Guest, C. Church, J. and links to: Related articles Show Copyright © 2004, BMJ Publishing Group Ltd. BMJ. 2004 September 25; 329(7468): 712. Olfactory detection of human bladder cancer by dogs: proof of principle study Carolyn M Willis, senior research scientist , 1 Susannah M Church, honorary research fellow , 1 Claire M Guest, operations director , 2 W Andrew Cook, deputy chief executive , 2 Noel McCarthy, medical statistician , 3 Anthea J Bransbury, associate specialist , 1 Martin R T Church, honorary research fellow ...

For research use only A215- Urinary bladder cancer tissues (formalin fixed) Specifications: • No. of cases: 45 • Tissue type: Urinary bladder cancer tissues • No. of spots: 2 spots from each cancer case (90 spots) 4 non-neoplastic spots (4 spots) •Total spots: 94 • Corresponding normal tissues with cancers: Yes • Diameter: 1. 0 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: 1 2 3 4 5 6 7 8 9 10 11 A B C D E F G H I : Urothelial carcinoma : Urothelial carcinoma in situ : Adenocarcinoma + other pathology : Squamous carcinoma : Non-neoplastic Page 2 ...

ReviewöBladder Cancer Neoadjuvant Chemotherapy in Invasive Bladder Cancer : Update of a Systematic Review and Meta-Analysis of Individual Patient Data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Meta-analysis Group, Medical Research Council Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK Accepted 6 April 2005 Available online 21 April 2005 Abstract Objectives: To update a systematic review and meta-analysis that assesses the effect of neoadjuvant chemotherapy in the treatment of patients with invasive bladder cancer . Methods: Following a prespecified protocol, we analysed updated individual patient data from all eligible randomised controlled trials that compared neoadjuvant chemotherapy plus local treatment with the same local treatment alone. Results: Updated results are based on 11 trials, 3005 patients; comprising 98% of all ...

ReviewöBladder Cancer Adjuvant Chemotherapy in Invasive Bladder Cancer : ASystematic Review and Meta-Analysis of Individual Patient Data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Meta-analysis Group, Medical Research Council Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK Accepted 6 April 2005 Available online 25 April 2005 Abstract Objectives: To evaluate the effect of adjuvant chemotherapy in invasive bladder cancer . Methods: We conducted a systematic review and meta-analysis of updated individual patient data from all available randomised controlled trials comparing local treatment plus adjuvant chemotherapy versus the same local treatment alone. Results: Analyses were based on 491 patients from six trials, representing 90% of all patients randomised in cisplatin-based combination chemotherapy trials and 66% of patients from all ...

Wednesday March 22, Former bladder patients in cancer scare Hospitals around Australia have been urged to trace more than 200 former patients who underwent a type of bladder surgery since 1980 amid fears some may be at greater risk of contracting cancer . Melbourne's Royal Children's Hospital and the Monash Medical Centre are trying to contact 96 of their former patients who, over more than two decades, underwent bladder augmentation surgery using bowel tissue. Royal Children's Hospital's head of urology Alan Woodward said a link had been made between the procedure and bladder cancer . Already one case had been detected in Victoria - a man who contracted bladder cancer after the procedure but had since recovered, Mr Woodward said. There was a second case in South Australia, although it was slightly different because that patient already had cancer before the surgery. Mr Woodward urged other hospitals ...

Introduction The progress against bladder cancer over the last 20 years and the current diagnosis and treatment strategies for managing the disease have been the subject of many studies (Droller, 1998 and Sens et al ., 2000). Transitional cell carcinoma of bladder is the fourth most common cancer in men and the fifth in women. The number of cases O bjective : Metallothionein (MT) is a low molecular –weight protein with high affinity for heavy metals, and is believed to play an important role in tumorigenesis. The goals of this study were to define the expression of MT as a new marker in human transitional cell carcinoma (TCC), and to correlate its expression with histologic grade and growth pattern of the tumours. Methods : The study was performed on 46 tissue sections of TCC with different grades, 12 sections of chronic cystitis and 7 normal bladder mucosa using immunohistochemistry. ...

Introduction Bladder cancer accounts for approximately 5% of all human cancers and represents 95% of all urothelial tumors (Izadifar et al ., 1999). Transitional cell carcinomas (TCC) represent 90% of bladder cancer , while squamous cell carcinomas (SCC) account only for 3-7% (Cotran et al. , 1994). SCC of the bladder are uncommon in the developed countries; while in areas endemic for schistosomiasis, these O bjective: the present study aimed to investigate the pattern of expression of epidermal growth factor receptor (EGFR) and transforming growth factor a (TGF-a) in transitional cell carcinoma (TCC) and squamous cell carcinoma (SCC) of the urinary bladder and to correlate their expression with tumor grading. Methods: The work was performed on 28 cases of TCC and 12 cases of SCC using immunohistochemistry. Results: For both markers, positive staining reaction ...

Cancer Mortality by Remoteness Category in Queensland Bladder cancer 0 3 6 9 12 15 18 0 3 6 9 12 15 18 Male Female Rate per 100,000 population Rate per 100,000 population Avg No. Avg No. per Year per Year Mortality of Bladder cancer , by ARIA+ Category and Sex, Queensland, Five Year Average, 1998 to 2002 8.4 59 2.4 25 Major City ARIAplus Category 7.9 34 2.1 11 Inner Regional 7.6 16 2.1 6 Outer Regional 7.7 1 0.0 0 Remote 7.3 1 4.4 1 Very remote Note: Rates are age standardised to the Australian population as at 30 June 2001. Numbers and rates are averaged over five ...

Developing a Blaise Instrument for the Spanish Bladder Cancer Study Richard Frey, Westat, U.S. I. Introduction The Spanish Bladder Cancer Study (SBC) is an occupational health epidemiologic study that has involved development and programming of an innovative Blaise computer assisted personal interviewing (CAPI) system for administering, in Spanish, seven core health study sections and sixty-three occupational module questionnaires. There are other study components that involve hospital case ascertainment and control selection in multiple hospital locations throughout Spain, along with a self- administered dietary history questionnaire and blood, urine and toenails specimen collection and shipment. The study is, however, mainly characterized by a large Blaise CAPI system with technically complex programming requirements, an extremely tight design and development schedule, and international study implementation ...

May 3, 2006 MZT Matritech, Inc. Henry McCusker 617.236.6396 hwm@scimitarequity.com Please read the important Disclosures Section At the end of this review Detecting Bladder Cancer Tumors Conventional Methods Miss Ranking: “BUY” Price at 5/02/06 : $1.23 52 Week Range : $1.56 - $0.52 New Price Target: $2.50 - $2.75 Market Capitalization: $64.91 m Enterprise Value: $65.75 m Shares Outstanding: 52.78 m Fiscal Year End: Dec Exchange: AMEX Building on momentum The clinical performance of MZT’s NMP22® BladderChek® Test, the point-of-care urine test, in detecting occult bladder cancers was recently presented at the 21st Annual Congress of the European Association of Urology (EAU) in Paris. The NMP22 BladderChek Test was reported ...

bladder cancer 1185 Professor Per-Anders Abrahamsson - Selected abstracts Correlation of P16INK4 Expression in Renal Cell Carcinoma with Clinicopathological Parameters Ikuerowo S.O. 1 , Kuczyk M.A. 2 , Von Wasielewski R. 3 , Shittu O.B. 1 , Jonas U. 4 , Machtens S. 4 , Serth J. 4 1 University College Hospital And University Of Ibadan, Urology, Ibadan, Nigeria, 2 Eberhard Karls Universität, Urology, Tübingen, Germany, 3 Medizinische Hochschule Hannover, Pathology, Hannover, Germany, 4 Medizinische Hochschule Hannover, Urology, Hannover, Germany Introduction & objectives The tumour suppressor p16INK4 is a cell cycle inhibitor, which arrests cellular replication via binding to a complex of cyclins and cyclin dependent kinases and inhibition of RB protein phosphorylation. Though inactivation of the p16 gene due to homozygous deletion or ...

Guidelines on Bladder Cancer Muscle-invasive and Metastatic G. Jakse, F. Algaba, S. Fossa, A. Stenzl, C. Sternberg © European Association of Urology 2006 Page 2 TABLE OF CONTENTS PAGE 1 INTRODUCTION 4 2 CLASSIFICATION 4 2.1 TNM staging 4 2.2 Histological grading 4 2.3 References 5 3 RISK FACTORS 5 4 DIAGNOSIS 5 4.1 Symptoms 5 4.2 Physical examination 5 4.3 Cystoscopy and Transurethral Resection (TUR) 5 4.4 References 5 5 STAGING 6 5.1 T-staging 6 5.1.1 TUR and bimanual palpation 6 5.1.2 Imaging 6 5.1.2.1 Intravenous pyelography 6 5.1.2.2 Ultrasonography 6 5.1.2.3 Computed tomography (CT) 6 5.1.2.4 Magnetic ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN BLADDER CANCER TISSUE ARRAY Catalog Number: TMA-132 Each dot represents a DISEASED tissue spot from one individual specimen that was selected and pathologically confirmed ( Bladder carcinoma tissue array) Cases: 60 Cores: 63 Diameter: 1.5mm Thickness: 5 µm Standard IHC: PCNA confirmed Layout : 7 x 9 1 2 3 4 5 6 7 8 9 A 1 2 3 4 5 6 7 8 9 B 10 11 12 13 14 15 16 17 18 C 19 20 21 22 23 24 25 26 27 D 28 29 30 31 32 33 34 35 36 ...

A215- Urinary bladder cancer tissues (formalin fixed) For research use only Specifications: • No. of cases: 45 • Tissue type: Urinary bladder cancer tissues • No. of spots: 2 spots from each cancer case (90 spots) 4 non-neoplastic spots (4 spots) •Total spots: 94 • Corresponding normal tissues with cancers: Yes • Diameter: 1. 0 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: 1 2 3 4 5 6 7 8 9 10 11 A B C D E F G H I : Urothelial carcinoma : Urothelial carcinoma in situ : Adenocarcinoma + other pathology : Squamous carcinoma : Non-neoplastic Page 2 ...

Trends in Cancer Mortality by Health Zone in Queensland Bladder cancer Rate per 100,000 population Mortality of Bladder cancer , by Health Zone, Queensland, 1986 to 2002 Northern Central Southern 0 3 6 9 12 15 Year 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 Note: Rates are age standardised to the Australian population as at 30 June 2001. Data are reported by place of usual residence and year of diagnosis. Bladder cancer is defined by the ICD-0-2 codes of C67 Source: Queensland Cancer Registry, Queensland Health and Queensland Cancer Fund. Generated by Epidemiology Services Unit, Queensland Health For more information: Health Status Indicators for Queensland Queensland ...

Chapter II.8 II.8-1 Cost of Bladder Cancer C HAPTER II.8. C OST OF B LADDER C ANCER Clicking on the sections below will take you to the relevant text. II.8.A Background II.8.A.1 Description II.8.A.2 Concurrent Effects II.8.A.3 Causality & Special Susceptibilities II.8.A.4 Treatments and Services II.8.A.5 Prognosis II.8.B Costs of Treatments and Services II.8.B.1 Methodology II.8.B.2 Results of Medical Cost Analysis II.8.B.3 Other Studies II.8.C Uncertainties and Limitations II.8.C.1 Uncertainties Surrounding Key Inputs to the Analysis II.8.C.2 Scope of the Analysis Page 2 Chapter II.8 II.8-2 Cost of Bladder ...

Measurements using the alkaline comet assay predict bladder cancer cell radiosensitivity MAL Moneef 1 , BT Sherwood 1,2 , KJ Bowman 1 , RC Kockelbergh 2 , RP Symonds 3 , WP Steward 3 , JK Mellon 2 and GDD Jones * ,1 1 Department of Cancer Studies and Molecular Medicine, Hodgkin Building, University of Leicester, Lancaster Road, PO Box 138, Leicester LE1 9HN, UK; 2 University Division of Urology, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK; 3 University Department of Cancer Studies and Molecular Medicine, Osborne Building, Leicester Royal Infirmary, Leicester LE1 5WW, UK In the UK, the two main treatments of invasive bladder cancer are radiotherapy or cystectomy. However, B50% of patients ...

bladder cancer 1581 Toenail arsenic and bladder cancer : findings from a cohort study of male smokers Dominique S. Michaud Assistant Professor Department of Epidemiology Harvard School of Public Health, Boston Outline Arsenic and bladder cancer High dose studies Low dose studies Arsenic measurements in toenails Methods: ATBC study Results Discussion Future directions High arsenic levels and bladder cancer Ecological studies have consistently reported elevated mortality rates of bladder cancer in arsenic endemic areas: Taiwan Argentina northern Chile High arsenic levels and bladder cancer Elevated bladder cancer incidence and ...

Toxicology 207 (2005) 49–57 Effects of arsenite on cell cycle progression in a human bladder cancer cell line A. Hernandez-Zavala a , c , E. Cordova d , L.M. Del Razo a , M.E. Cebrian a , E. Garrido b , * a Seccíon de Toxicologia, CINVESTAV-IPN, Av. Instituto Politecnico Nacional, No. 2508, Col. San Pedro Zacatenco, C.P. 07360, Mexico b Departamento de Genetica y Biologia Molecular, CINVESTAV-IPN, Av. Instituto Politecnico Nacional, No. 2508, Col. San Pedro Zacatenco, Mexico City, C.P. 07360, Mexico c Instituto Nacional de Salud Publica, Av. Universidad No. 655, Col. Santa Maria Ahuacatitlan, Cuernavaca, Morelos, C.P. 62508, Mexico d Departamento de Bioqúimica, Instituto de Fisiologia Celular, UNAM. Circuito Exterior S/N, Ciudad Universitaria, C.P. 04510, Mexico ...